Vor Biopharma Inc. Stock Price, News & Analysis

PureTech Health reported strong results for 2024, highlighting significant clinical and financial achievements. The company's wholly-owned deupirfenidone showed positive Phase 2b results in IPF treatment, while LYT-200 demonstrated promising outcomes in cancer trials. A major milestone was the FDA approval of Cobenfy for schizophrenia.

The company maintained a robust financial position with $366.8 million in cash at PureTech level as of December 2024, providing operational runway into 2027. Notable achievements include their Founded Entity, Seaport Therapeutics, raising over $325 million.

Key developments include positive results from the ELEVATE IPF trial, with deupirfenidone showing potential to stabilize lung function. The company plans to initiate Phase 3 trials by end of 2025, subject to FDA feedback. PureTech's innovation engine has produced 29 therapeutic candidates, with three achieving FDA approval.

Vor Bio (VOR) has reported its Q4 and full-year 2024 financial results, highlighting progress in its cell and genome engineering platform. The company completed a $55.6 million private placement in December 2024, led by Reid Hoffman and RA Capital Management.

Key clinical updates include data from 25 patients treated with trem-cel, of which 15 received Mylotarg. The trial demonstrated durable engraftment and improved relapse-free survival. The VCAR33 clinical trial continues with strong enrollment, with data updates planned for H1 2025. The company plans to initiate the trem-cel+VCAR33 Treatment System clinical trial in H2 2025.

Financial highlights: Cash position of $91.9 million as of December 31, 2024, funding operations into Q1 2026. Q4 2024 R&D expenses were $25.3M (vs $20.9M in Q4 2023), while G&A expenses decreased to $6.0M (vs $7.2M in Q4 2023). Net loss for Q4 2024 was $30.7M compared to $26.3M in Q4 2023.

Vor Bio (VOR) presented research at the TANDEM Meetings highlighting challenges in cell and gene therapy (CGT) clinical trial enrollment. The study, involving 30 healthcare professionals and patient advocacy partners, identified key barriers including trial complexity, logistical challenges, and resource constraints at trial sites.

Key findings revealed that CGT trial enrollment requires more time compared to non-CGT trials due to complexity and patients' need for additional support. Despite these challenges, 100% of surveyed participants continue offering these trials to patients. Common patient concerns include fears about gene editing risks and caregiver requirements.

The research suggests opportunities for improvement through comprehensive educational content and specialized CGT research teams at institutions. The study included collaboration with notable institutions such as NMDP, MDS Foundation, Memorial Sloan Kettering Cancer Center, and Stanford Medicine.

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The company will engage in a fireside chat scheduled for Wednesday, February 12th at 12:00pm ET and conduct virtual one-on-one meetings with investors.

The event will be held virtually, and interested parties can access both the live webcast and archived replay of the fireside chat through the investors section of www.vorbio.com.

Vor Bio (Nasdaq: VOR) has appointed Mr. Erez Kalir to its Board of Directors, creating a new board seat following a recent private investment in public equity (PIPE) financing led by Reid Hoffman. Kalir will serve as director designee of Hoffman's investment fund, Reprogrammed Interchange,

Currently Managing Member of Martial Eagle Fund and Venture Partner at FJ Labs, Kalir brings extensive experience in biotech investments and entrepreneurship. He authors the Biotech Frontiers newsletter for Porter & Co. and previously worked at Tiger Management with Julian H. Robertson, advising on biotech and healthcare investments.

Kalir's appointment strengthens Vor Bio's leadership as the company advances its trem-cel platform and VCAR33 through regulatory approval. His background includes an MSc in cell biology from Oxford as a Rhodes Scholar, a JD from Yale Law School, and an A.B. from Stanford University.

Vor Bio (Nasdaq: VOR) has secured a $55.6 million private placement investment (PIPE), led by new investor Reid Hoffman with participation from existing stockholder RA Capital Management. The company will issue approximately 55.9 million shares of common stock and warrants to purchase about 69.8 million shares at $0.99425 per share and accompanying warrants. The warrants, exercisable through 2031 at $0.838 per share, could generate additional proceeds of up to $58.5 million.

The company plans to announce updated clinical data from two trials in 2025: the Phase 1/2 VBP301 trial of VCAR33ALLO in H1 and the Phase 1/2a VBP101 trial of trem-cel with Mylotarg in H2. Both Hoffman and RA Capital Management will receive one board seat and one board observer seat. The funding extends Vor Bio's cash runway through the release of these trial updates.

Vor Bio has released updated clinical data from its Phase 1/2 VBP101 study of trem-cel followed by Mylotarg in relapsed/refractory AML patients. The study showed promising results with 25 patients treated with trem-cel, of which 15 received Mylotarg. Key findings include improved relapse-free survival, successful blood system shielding, and reliable engraftment with 100% of patients achieving primary neutrophil engraftment (median 9.5 days).

The company received supportive feedback from the FDA regarding their registrational trial design, with agreement on study population, control arm, primary endpoint, stratification factors, and statistical design. The FDA acknowledged trem-cel's neutrophil and platelet engraftment capabilities and its safety profile comparable to unedited CD34+ grafts.

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in the Stifel 2024 Healthcare Conference. The company will engage in a fireside chat scheduled for Monday, November 18, 2024, at 2:25 pm ET in New York, NY. Additionally, Vor Bio will host one-on-one investor meetings during the conference. Interested parties can access both live webcast and archived replay of the fireside chat through the investors section of the company's website at www.vorbio.com.

Vor Bio reported Q3 2024 financial results and corporate updates. The company's net loss decreased to $27.6M from $33.2M year-over-year. Cash position stands at $62.8M, projected to fund operations into H2 2025. R&D expenses decreased to $21.8M from $27.6M, while G&A expenses reduced to $6.7M from $7.7M. Clinical progress includes 25 patients dosed with trem-cel and 6 patients receiving Mylotarg at 2 mg/m2. The company appointed Han Choi as CFO and plans to present updated clinical data at the upcoming ASH annual meeting.